Explanation of price changes and reimbursement after acalatinib is included in medical insurance

Acalabrutinib (Acalabrutinib), as a highly effective BTK inhibitor, has been officially launched in China and has been successfully included in the national medical insurance directory. This policy adjustment is of great significance to patients, significantly reducing the economic burden of medication and allowing more patients with indications to receive standardized and continuous treatment support. Previously, the price of acotinib in the domestic market was relatively high, close to more than 20,000 yuan per box, which put great pressure on patients.

After being included in medical insurance, patients who purchase acotinib can enjoy a certain proportion of medical insurance reimbursement. The specific reimbursement amount and proportion vary due to differences in regional medical insurance policies. Under normal circumstances, the actual amount paid by patients will drop significantly, effectively alleviating the pressure on treatment costs and promoting the popularity and clinical application of drugs. It is recommended that patients consult the local hospital pharmacy or medical insurance department in detail when purchasing medicines to understand the specific reimbursement policies and procedures to ensure that they enjoy the medical insurance benefits they deserve.

In comparison, the prices of generic acotinib drugs in foreign markets are generally more affordable, especially the Laos version, which costs about more than 3,000 yuan, which is far lower than the price of the domestic original drug. The ingredients of this generic drug are basically the same as those of the domestic original drug, and it has good efficacy guarantee. It has become the choice for some patients to obtain drugs through overseas channels. However, patients should pay attention to regular channels and drug quality when purchasing, and avoid buying fake and shoddy products due to price temptation.

Overall, the inclusion of acotinib in medical insurance has greatly improved the drug accessibility and affordability of domestic patients. Combined with the price advantages of foreign generic drugs, patients can reasonably choose drug purchase channels based on their actual conditions. At the same time, with the continuous improvement of medical insurance policies and the adjustment of drug prices, the treatment coverage and clinical value of acotinib are expected to be further expanded in the future, bringing good news to more patients.

Reference materials:https://www.drugs.com